![Favorite pages[Japanese page]](/files/000137013.png){kind=small}
](/files/000137010.png){kind=small}
Here begins the text.
Pmda Pharmaceuticals and Medical Devices Agency
What's newBack number
June 22, 2021JP 18th Edition (Japanese version) posted
- June 21, 2021Revisions of PRECAUTIONS: Nivolumab (genetical recombination) posted
- June 21, 2021List of Approved Products: FY 2020 (April 2020 - March 2021)
- June 17, 2021Global Pharmaceutical Quality Knowledge Management: Enhancing Regulatory Reliance and Agility
- June 17, 2021Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness (Revised 11 June 2021)
- June 17, 2021Joint Statement on transparency and data integrity International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO)
- June 17, 2021China and Japan Regional Joint Public Meeting on ICH
- June 16, 2021English Translation of Review Report: Comirnaty, Opdivo (Partial Change Approval), Orkedia (Partial Change Approval), and Velexbru (Partial Change Approval)
- June 10, 2021MHLW Pharmaceuticals and Medical Devices Safety Information No.383
- June 10, 2021Joint MHLW/PMDA-USP Workshop schedule program have been updated
- Currently, there is no applicable information.
- June 22, 2021JP 18th Edition (Japanese version) posted
- June 17, 2021Global Pharmaceutical Quality Knowledge Management: Enhancing Regulatory Reliance and Agility
- June 17, 2021Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness (Revised 11 June 2021)
- June 17, 2021Joint Statement on transparency and data integrity International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO)
